Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilengitide plus standard chemoradiotherapy in newly diagnosed glioblastoma with MGMT promoter methylation
2007-004344-78Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Apr 2008
- Modality
- Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cilengitide in glioblastoma (GBM) (2 arms), sponsored by Merck KGaA. Primary endpoint: Overall survival time. Started Apr 2008; status: completed.
02
Drugs
cilengitide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2007-004344-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004344-78.